Trial Profile
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Abiraterone acetate; Prednisolone; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms ACIS
- Sponsors Aragon Pharmaceuticals; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
- 26 Mar 2024 Planned End Date changed from 1 Dec 2025 to 31 Dec 2025.
- 27 Feb 2024 Planned End Date changed from 1 Dec 2026 to 1 Dec 2025.
- 05 Dec 2023 Planned End Date changed from 31 Dec 2024 to 1 Dec 2026.